Tislelizumab plus chemo or radiation for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether adding tislelizumab to chemotherapy or radiation can work better for older adults with advanced or recurrent/metastatic esophageal squamous cell cancer. The goal is to slow the cancer down and improve control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 70 or older.
- Your cancer is esophageal squamous cell cancer, confirmed by pathology (tissue testing).
- Your cancer is advanced, recurrent, or metastatic and cannot be removed by surgery.
- You have not had any stomach/esophageal cancer treatment by mouth or IV before starting the study (including chemo, targeted therapy, immunotherapy).
- You have at least one measurable tumor spot the study team can track.
- Your blood counts, liver, and kidney tests are within study limits, and you can follow study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
This trial tests if adding the immunotherapy drug tislelizumab to standard chemotherapy before surgery or radiation can improve outcomes for people with resectable esophageal squamous cell carcinoma. It is designed for patients whose cancer is in the chest and has not spread to distant organs.
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This trial tests different schedules of tislelizumab (an immunotherapy drug) combined with chemotherapy for Japanese patients with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. It aims to find a better way to give these treatments together.
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.